107 related articles for article (PubMed ID: 32343987)
1. Hsp90 facilitates acquired drug resistance of tumor cells through cholesterol modulation however independent of tumor progression.
Kumar P; Devaki B; Jonnala UK; Amere Subbarao S
Biochim Biophys Acta Mol Cell Res; 2020 Aug; 1867(8):118728. PubMed ID: 32343987
[TBL] [Abstract][Full Text] [Related]
2. Novel Heat Shock Protein 90 Inhibitors Suppress P-Glycoprotein Activity and Overcome Multidrug Resistance in Cancer Cells.
Dinić J; Podolski-Renić A; Jovanović M; Musso L; Tsakovska I; Pajeva I; Dallavalle S; Pešić M
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31527404
[TBL] [Abstract][Full Text] [Related]
3. P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response.
McCollum AK; TenEyck CJ; Stensgard B; Morlan BW; Ballman KV; Jenkins RB; Toft DO; Erlichman C
Cancer Res; 2008 Sep; 68(18):7419-27. PubMed ID: 18794130
[TBL] [Abstract][Full Text] [Related]
4. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance.
Zhang H; Neely L; Lundgren K; Yang YC; Lough R; Timple N; Burrows F
Int J Cancer; 2010 Mar; 126(5):1226-34. PubMed ID: 19676042
[TBL] [Abstract][Full Text] [Related]
5. Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1.
Kim HB; Lee SH; Um JH; Oh WK; Kim DW; Kang CD; Kim SH
Oncotarget; 2015 Nov; 6(34):36202-18. PubMed ID: 26416354
[TBL] [Abstract][Full Text] [Related]
6. Co-Inhibition of P-gp and Hsp90 by an Isatin-Derived Compound Contributes to the Increase of the Chemosensitivity of MCF7/ADR-Resistant Cells to Doxorubicin.
Abdalla AN; Di Stefano M; Poli G; Tuccinardi T; Bader A; Vassallo A; Abdallah ME; El-Readi MZ; Refaat B; Algarni AS; Ahmad R; Alkahtani HM; Abdel-Aziz AA; El-Azab AS; Alqathama A
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011321
[TBL] [Abstract][Full Text] [Related]
7. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
[TBL] [Abstract][Full Text] [Related]
8. Tumor Suppression Efficacy of Heat Shock Protein 90 Inhibitor 17AAG in a Liposarcoma Mouse Model.
Nam S; Kim H; Hong D; Park JB; Kim SJ
Anticancer Res; 2017 Nov; 37(11):6291-6302. PubMed ID: 29061812
[TBL] [Abstract][Full Text] [Related]
9. Altered molecular pathways decides the treatment outcome of Hsp90 inhibitors against breast cancer cells.
Vykuntham NG; Suran S; Siripini S; John S; Kumar P; Paithankar K; Amere Subbarao S
Toxicol In Vitro; 2020 Jun; 65():104828. PubMed ID: 32184171
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of chemo-resistant human chronic myeloid leukemia stem-like cells to Hsp90 inhibitor by SIRT1 inhibition.
Kim HB; Lee SH; Um JH; Kim MJ; Hyun SK; Gong EJ; Oh WK; Kang CD; Kim SH
Int J Biol Sci; 2015; 11(8):923-34. PubMed ID: 26157347
[TBL] [Abstract][Full Text] [Related]
11. The matrix metalloproteinase 7 (MMP7) links Hsp90 chaperone with acquired drug resistance and tumor metastasis.
Kumar P; Siripini S; Sreedhar AS
Cancer Rep (Hoboken); 2022 Dec; 5(12):e1261. PubMed ID: 32761892
[TBL] [Abstract][Full Text] [Related]
12. Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer.
Kang BH; Siegelin MD; Plescia J; Raskett CM; Garlick DS; Dohi T; Lian JB; Stein GS; Languino LR; Altieri DC
Clin Cancer Res; 2010 Oct; 16(19):4779-88. PubMed ID: 20876793
[TBL] [Abstract][Full Text] [Related]
13. Acquired resistance to HSP90 inhibitor 17-AAG and increased metastatic potential are associated with MUC1 expression in colon carcinoma cells.
Liu X; Ban LL; Luo G; Li ZY; Li YF; Zhou YC; Wang XC; Jin CG; Ye JG; Ma DD; Xie Q; Huang YG
Anticancer Drugs; 2016 Jun; 27(5):417-26. PubMed ID: 26872308
[TBL] [Abstract][Full Text] [Related]
14. The conformation-specific Hsp90 inhibition interferes with the oncogenic RAF kinase adaptation and triggers premature cellular senescence, hence, acts as a tumor suppressor mechanism.
Kanugovi Vijayavittal A; Amere Subbarao S
Biochim Biophys Acta Mol Cell Res; 2021 Mar; 1868(3):118943. PubMed ID: 33359710
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
16. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis.
Koizumi H; Yamada T; Takeuchi S; Nakagawa T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Yano S
J Thorac Oncol; 2012 Jul; 7(7):1078-85. PubMed ID: 22592212
[TBL] [Abstract][Full Text] [Related]
17. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
18. Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
Qian J; Xia M; Liu W; Li L; Yang J; Mei Y; Meng Q; Xie Y
Eur J Pharmacol; 2019 Jun; 852():231-243. PubMed ID: 30959046
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein-evading anti-tumor activity of a novel tubulin and HSP90 dual inhibitor in a non-small-cell lung cancer model.
Zhang Q; Zhai S; Li L; Li X; Jiang C; Zhang C; Yan B
J Pharmacol Sci; 2014; 126(1):66-76. PubMed ID: 25185500
[TBL] [Abstract][Full Text] [Related]
20. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
Ying W; Du Z; Sun L; Foley KP; Proia DA; Blackman RK; Zhou D; Inoue T; Tatsuta N; Sang J; Ye S; Acquaviva J; Ogawa LS; Wada Y; Barsoum J; Koya K
Mol Cancer Ther; 2012 Feb; 11(2):475-84. PubMed ID: 22144665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
